Three-Plant FDA Warning Spooks Dr Reddy's, Clouds ANDAs
This article was originally published in Scrip
Executive Summary
Dr Reddy's Laboratories was bludgeoned on Indian bourses after the firm said that it had received FDA warning letters at three manufacturing sites, including an oncology plant, in India.